ClinicalTrials.gg
RecruitingNCT06459973Updated Dec 23, 2025

A Clinical Study of YL205 in Patients With Advanced Solid Tumors

A Phase 1/2 interventional study of intravenous (IV) infusion in Advanced Solid Tumors, sponsored by MediLink Therapeutics (Suzhou) Co., Ltd.. Recruiting at 43 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-23.

Sponsored by MediLink Therapeutics (Suzhou) Co., Ltd. · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2024; still recruiting 2 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
252
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study is a multicenter, open-label, phase I/II study of YL205 in China to evaluate the safety, tolerability, PK characteristics and preliminary efficacy of YL205 in the following selected patients with advanced solid tumors.

02

Conditions studied

  • Advanced Solid Tumors
03

In context

Lead sponsor

MediLink Therapeutics (Suzhou) Co., Ltd. is the lead sponsor of 23 studies on the registry; 18 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1) Subjects who are informed of relevant information of the study prior to initiation of the study and voluntarily sign and date on the form (ICF).

    2) Age ≥18 years. 3) Be willing to follow and be able to complete all the study procedures. 4) (BMI) within the range of 18 to 32 kg/m2, and body weight ≥45kg for female subjects.

    5) Patients with or cytologically confirmed locally advanced or ovarian cancer (OC), non-squamous non-small cell lung cancer (NSQ NSCLC), renal cell carcinoma (RCC), endometrial cancer (EC), or other Napi2b-overexpressing tumors。 6) Patients with positive Napi2b test results at the central laboratory. 9) At least one radiologically evaluable lesion for subjects in Part 1; At least one measurable extracranial lesion (non-radiation fields) for subjects in Part 2 and Part 3.

    10) Expected survival ≥3 months. 11) Female subjects of must agree to take effective measures and must not undergo egg donation or egg retrieval for their own use from screening throughout the study period and for at least 6 months after the last dose of the drug. Male subjects must agree to take effective contraceptive measures and must not undergo sperm cryopreservation or sperm donation from screening throughout the study period and for at least 6 months after the last dose of the investigational drug.

    12) subjects must provide tumor samples. 13) Subjects who are capable of and willing to comply with the visits and procedures stipulated in the study protocol.

Exclusion criteria

Exclusion Criteria:

  • 1) Subjects with a treatment history with drugs targeting Napi2b. 2) Subjects with a history of intolerance to topoisomerase I inhibitors or ADC therapy.

    3) Subjects who are participating in another clinical study, with the exception an of observational (non-interventional) clinical study or the follow-up period of an interventional study.

    4) Subjects with an insufficient from the previous anti-tumor therapy to the first dose.

    5) Subjects who received radiotherapy, including palliative stereotactic radiotherapy on the abdomen, within 4 weeks prior to the first dose.

    6) Subjects who received major surgery within 4 weeks prior to the first dose or those who plan to receive major surgery during the study.

    7) Subjects who received bone marrow transplantation or solid organ transplantation.

    8) Subjects who received systemic or other treatment within 2 weeks prior to the first dose of the drug.

    9) Subjects who received any within 4 weeks prior to the first dose or those who plan to receive live vaccines during the study.

    10) Subjects with a medical history of carcinoma or cancerous meningitis.

    11) Subjects with or spinal cord compression. 12) Subjects with uncontrolled or cardiovascular and cerebrovascular diseases.

    13) Subjects who were diagnosed with Gilbert's syndrome. 14) Subjects with significantly symptomatic or unstable effusion in the third space requiring repeated drainage.

    15) Subjects with medical history of gastrointestinal perforation and/or fistula within 6 months prior to the first dose, or active gastric ulcers, duodenal ulcer, colitis ulcerative, or other gastrointestinal disorders that may cause hemorrhage or perforation in the opinion of the investigator.

    16) Subjects with serious infection (Grade ≥3 as per v5.0) prior to the first dose.

    17) Subjects with (HIV), active virus (HBV) or virus (HCV) infection; subjects with positive syphilis antibody and a positive titer result.

    18) Subjects with unresolved toxicity caused by previous anti-tumor therapy. 20) Subjects with a history of serious allergic reactions to drugs, inactive ingredients in drug products, or other monoclonal antibodies.

    21) Female subjects who are pregnant as confirmed by a pregnancy test within 3 days prior to the first dose, or lactating women.

    22) Subjects who have any diseases, medical conditions, organ system dysfunction, or social conditions.

    23) Subjects with multiple primary within 5 years prior to the signing of the ICF, except for fully resected non-melanoma skin cancer, radically treated carcinoma in situ, or other radically treated solid tumors.

Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
252 participants (estimated)

Study arms

  • Experimental
    Phase Ia: Dose escalation portion

    YL205 is provided as the lyophilized powder, 160 mg/vial. Adcanced solid tumors patients will be given YL205 by intravenously once every 3 weeks (Q3W) as a cycle at several dose levels.

    Drug: intravenous (IV) infusion

  • Experimental
    Phase Ib: Dose expansion portion

    YL205 is provided as the lyophilized powder, 160 mg/vial. Adcanced solid tumors patients will be given YL205 by intravenously once every 3 weeks (Q3W) as a cycle at no less than two dose levels.

    Drug: intravenous (IV) infusion

  • Experimental
    Phase II: Cohort expansion portion

    YL205 is provided as the lyophilized powder, 160 mg/vial. Adcanced solid tumors patients will be given YL205 by intravenously once every 3 weeks (Q3W) as a cycle at RP2D.

    Drug: intravenous (IV) infusion

Interventions

  • Drugintravenous (IV) infusion

    YL205 is provided in the form of lyophilized powder under a strength of 160 mg/vial. Each vial should be reconstituted to 20 mg/mL. Prior to IV infusionSubjects will be treated with YL205 via intravenous (IV) infusion, once every 3 weeks (Q3W) as a treatment cycle

06

What researchers measure

Primary outcomes

  1. To evalue the DLTs

    Time frame: Approximately within 36 months

  2. To evalue the TEAEs

    Treatment Emergent Adverse Event

    Time frame: Approximately within 36 months

  3. To evalue the TRAEs

    Treatment Related Adverse Event

    Time frame: Approximately within 36 months

  4. To evalue the serious adverse events (SAEs)

    Time frame: Approximately within 36 months

  5. Determination of the MTD of YL205 in the pivotal clinical study

    Time frame: Approximately within 36 months

  6. Determination of the RED of YL205 in the pivotal clinical study

    Time frame: Approximately within 36 months

  7. Determination of the RP2D of YL205 in the pivotal clinical study

    Time frame: Approximately within 36 months

  8. Assessed ORR (the proportion of CR and PR) by the investigator per RECIST v1.1

    Time frame: Approximately within 36 months

Secondary outcomes

  1. Characterize the PK parameter AUC

    area under curve (AUC)

    Time frame: Approximately within 36 months

  2. Characterize the PK parameter Cmax

    maximum concentration (Cmax)

    Time frame: Approximately within 36 months

  3. Characterize the PK parameter Ctrough

    minimum concentration at trough (Ctrough)

    Time frame: Approximately within 36 months

  4. Characterize the PK parameter Vd

    volume of distribution (Vd)

    Time frame: Approximately within 36 months

  5. Characterize the PK parameter CL

    plasma clearance (CL)

    Time frame: Approximately within 36 months

  6. Characterize the PK parameter Tmax

    time to maximum concentration (Tmax)

    Time frame: Approximately within 36 months

  7. Characterize the PK parameter t1/2

    half-life (t1/2)

    Time frame: Approximately within 36 months

  8. Assessed the disease control rate (DCR) per RECIST v1.1

    (defined as the proportion of CR, PR, or stable disease (SD))

    Time frame: Approximately within 36 months

  9. Assessed the duration of response (DOR) per RECIST v1.1

    Time frame: Approximately within 36 months

  10. Assessed the time to response (TTR) per RECIST v1.1

    Time frame: Approximately within 36 months

  11. Assessed the progression free survival (PFS) per RECIST v1.1

    Time frame: Approximately within 36 months

  12. Assessed the depth of response (DpR) per RECIST v1.1

    the percentage change in target lesion size

    Time frame: Approximately within 36 months

  13. Assessed the overall survival (OS) per RECIST v1.1

    Time frame: Approximately within 36 months

  14. Evaluate the corelaton between different levels of Napi2B expression and the sum of CR rate, PR rate and SD rate

    Time frame: Approximately within 36 months

07

Study locations

43 of 43 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2024 (actual). Primary completion is estimated for Jul 2027, 37 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 30, 2024
First posted
Jun 14, 2024
StartActual
Jun 4, 2024
Primary completionEst.
Jul 31, 2027
CompletionEst.
Jul 31, 2030
Last update
Dec 23, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 23, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06459973
Responsible party
Sponsor
First posted
Jun 14, 2024
Start date
Jun 4, 2024
Primary completion
Jul 31, 2027 (estimated)
Completion
Jul 31, 2030 (estimated)
Last update
Dec 23, 2025

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion